Navigation Links
SARcode Bioscience Completes $44 Million Series B Financing
Date:7/18/2011

well tolerated. Ocular adverse events were mostly mild, transient and related to initial instillation of the drug. SARcode plans to initiate pivotal Phase 3 clinical studies with SAR 1118 in the second half of 2011. 

"We are extremely pleased with this financing, and are grateful for the confidence and trust from such renowned life-science investors," said Quinton Oswald, Chief Executive Officer of SARcode Bioscience.  "In the US alone, the current dry eye market potential is over $1 billion.  This is expected to grow substantially in the next decade due to an aging population and increased incidence of type 2 diabetes, both of which contribute to higher rates of dry eye disease.  There is clearly a large opportunity to develop therapeutic agents that can rapidly treat the signs of dry eye and improve symptomatic visual-related quality-of-life.  With the support of our investors, we look forward to bringing this novel dry eye therapy to the market."

About Dry Eye Syndrome

Dry eye syndrome is a prevalent and often chronic condition estimated to affect approximately 20 million people in the US.  It is among the most common diseases treated by ophthalmologists throughout the world, and has been shown to have a significant impact upon quality of life.  Dry eye varies in severity and etiology, and symptoms most commonly manifest as discomfort, visual disturbances, and tear film instability due to decreased quality or quantity of tears.  A major contributing factor towards the development of dry eye is inflammation caused by T-cell infiltration, proliferation and inflammatory cytokine production that can lead to reduction in tear film quality and ocular surface damage.

About SAR 1118

SAR 1118 is a potent novel small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18) antagonist under investigation for a broad range of ocular inflammatory conditions including
'/>"/>

SOURCE SARcode Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
2. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
3. Quinton Oswald Named Chief Executive Officer of SARcode Corporation
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... 31, 2014  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, 2014 at ... Conference, New York, NY Thursday, September ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:7/31/2014)... 2014 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... the development of its lead molecule, Anatabine Citrate, in ... selected Quotient Clinical, The Translational Pharmaceutics Company, based in ... run its early development programs. The Company ... the end of the third quarter with the Medicines ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
(Date:8/2/2014)... When the Black Hat conventioneers descend on Las Vegas ... can be always counted on, plenty of FUD will be ... doubt. The run-up has already made its share of ... on July 31st about how hackers could use a ... infect a system with malware, completely undetected, by leveraging the ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Cannabis use among ... teens aged 14 to 17 having used marijuana at least ... With their slogan “Say ‘No’ to Drugs, Say ‘Yes to ... reaching out to youth this summer with factual information about ... past six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ ...
(Date:8/1/2014)... a central role in regulating appetite and whole-body metabolism. ... brain,s control of food intake and body weight, but ... been unclear. A new study in the ... activity in a type of neuron known as pro-opiomelanocortin ... high-fat diet. Sabrina Diano and colleagues at Yale ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- The U.S. Food ... a new drug, Jardiance, to help fight type 2 ... or added to existing treatment regimens to control blood ... Curtis Rosebraugh, director of the Office of Drug Evaluation ... Research, said in an agency statement. The FDA ...
(Date:8/1/2014)... Summer is here, and with it comes ... summer, and they can be a pain for dogs. Animal ... all their customers get rid of ticks and prevent them ... in the summer, which is why they are so active ... and woodland areas and carry a number of diseases, including ...
Breaking Medicine News(10 mins):Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:Addressing a Serious Issue Affecting German Teens 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:Tis the Season for Tick Prevention 2
... University of New Hampshire finds that U.S. children are routinely ... previously recognized, with nearly half experiencing a physical assault in ... abuse and crime than do adults," said David Finkelhor, director ... study director. "If life were this dangerous for ordinary grown-ups, ...
... BANGKOK, Oct. 6 As thousands of experts around ... health and nutrition at the International Congress of Nutrition ... and Mars, Incorporated are acknowledging the important impact of ... Science - Flavanols and Sustainability," scientists will present evidence ...
... Los Angeles back surgeon, Dr. Rezaian of the California Orthopedic ... Spinal Stenosis . Open back surgery used to be ... pinching nerves, however, recent medical advances have given patients requiring ... of hope. Doctors have pioneered a new laser Spinal Stenosis ...
... ANGELES, Oct. 6 The Renaissance Laser and Vein Institute offers ... stretch marks and sagging skin like never before. Thanks to recent ... skin care lasers in the dermatological and cosmetic skin care world. ... is the Titan Procedure . The Titan laser ...
... Pelosi and the Democratic Women,s Working Group joined leaders from women,s ... discuss how women stand to gain the most ... face discrimination in both coverage and cost if health reform fails. ... , On Why Health Insurance Reform is Essential for ...
... D.D.S., who practices general dentistry in Flint, Mich., was inducted ... during a meeting of the ADA House of Delegates in ... presidency in October 2010 and will lead the more than ... Gist will be the ADA,s first African-American president. , Dr. ...
Cached Medicine News:Health News:New study finds high rates of childhood exposure to violence and abuse in US 2Health News:Cocoa Research Finds a Place in the Global Health Dialogue 2Health News:Cocoa Research Finds a Place in the Global Health Dialogue 3Health News:Cocoa Research Finds a Place in the Global Health Dialogue 4Health News:Cocoa Research Finds a Place in the Global Health Dialogue 5Health News:California Surgeon (laserbacksurgery.com) Pioneers Exciting Alternative to Traditional Spinal Stenosis Treatment 2Health News:Southern California Renaissance Laser and Vein Institute (laserandveinclinic.com) Offers Cutting Edge New Titan Procedure 2Health News:Pelosi: Health Insurance Reform Essential for Women 2Health News:Pelosi: Health Insurance Reform Essential for Women 3Health News:Pelosi: Health Insurance Reform Essential for Women 4Health News:Pelosi: Health Insurance Reform Essential for Women 5Health News:Michigan Dentist Chosen President-Elect of the American Dental Association 2
... Injection is supplied in an isotonic solution ... intravenous administration. Each milliliter contains 37 megabecquerels ... calibration time, made isotonic with 9 milligrams ... benzyl alcohol. The pH is adjusted to ...
... single-detector system offers general purpose ... for gurneys and wheelchairs. This ... versatile open gantry, caudal/cephalic detector ... for SPECT and whole body ...
Stainless steel lancet blade in stainless steel....
Sharp diamond shaped double blade in stainless steel....
Medicine Products: